Skip to main content

Table 3 ORRs of clinical symptoms in the IFNα1b group and the control group after days of treatment (%)

From: Efficacy and safety of aerosol inhalation of recombinant human interferon α1b (IFNα1b) injection for noninfluenza viral pneumonia, a multicenter, randomized, double-blind, placebo-controlled trial

Control group8765.51 ± 35.598266.26 ± 35.65
IFNα1b group7676.87 ± 25.156977.16 ± 24.19
P0.037 0.033